Bluejay Diagnostics Inc (BJDX) - Total Assets
Based on the latest financial reports, Bluejay Diagnostics Inc (BJDX) holds total assets worth $5.60 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Bluejay Diagnostics Inc to assess how comfortably operating cash covers total debt obligations.
Bluejay Diagnostics Inc - Total Assets Trend (2019–2025)
This chart illustrates how Bluejay Diagnostics Inc's total assets have evolved over time, based on quarterly financial data. See Bluejay Diagnostics Inc shareholders equity for net asset value and shareholders' equity analysis.
Bluejay Diagnostics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Bluejay Diagnostics Inc's total assets of $5.60 Million consist of 76.7% current assets and 23.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Bluejay Diagnostics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BJDX market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bluejay Diagnostics Inc's current assets represent 76.7% of total assets in 2025, an increase from 32.8% in 2019.
- Cash Position: Cash and equivalents constituted 72.6% of total assets in 2025, up from 10.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Bluejay Diagnostics Inc Competitors by Total Assets
Key competitors of Bluejay Diagnostics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Stratec SE
XETRA:SBS
|
Germany | €443.38 Million |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
Novacyt
PA:ALNOV
|
France | €40.28 Million |
|
HeraMED Limited
F:1I4
|
Germany | €1.49 Million |
|
Implanet SA
PA:ALIMP
|
France | €18.45 Million |
Bluejay Diagnostics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.81 | 2.71 | 0.84 |
| Quick Ratio | 2.81 | 2.71 | 0.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.55 Million | $2.26 Million | $-516.18K |
Bluejay Diagnostics Inc - Advanced Valuation Insights
This section examines the relationship between Bluejay Diagnostics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.33 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 6.9% |
| Total Assets | $7.12 Million |
| Market Capitalization | $889.85K USD |
Valuation Analysis
Below Book Valuation: The market values Bluejay Diagnostics Inc's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bluejay Diagnostics Inc's assets grew by 6.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bluejay Diagnostics Inc (2019–2025)
The table below shows the annual total assets of Bluejay Diagnostics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.12 Million | +6.94% |
| 2024-12-31 | $6.66 Million | +36.74% |
| 2023-12-31 | $4.87 Million | -63.99% |
| 2022-12-31 | $13.52 Million | -35.67% |
| 2021-12-31 | $21.02 Million | +1285.25% |
| 2020-12-31 | $1.52 Million | +65.55% |
| 2019-12-31 | $916.52K | -- |
About Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoas… Read more